Mark Yarchoan

AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma

Amit G. Singal, Josep M. Llovet, Mark Yarchoan et al. · Hepatology · 2023 · 1.4K citations · Full text

Cancer Management, Pathology, Aasld Practice Guidance +19

PD-L1 expression and tumor mutational burden are independent biomarkers in most cancers

Mark Yarchoan, Lee A. Albacker, Alexander C. Hopkins et al. · JCI Insight · 2019 · 526 citations · Full text

Neoadjuvant cabozantinib and nivolumab convert locally advanced hepatocellular carcinoma into resectable disease with enhanced antitumor immunity

Won Jin Ho, Qingfeng Zhu, Jennifer N. Durham et al. · Nature Cancer · 2021 · 327 citations · Full text

Nivolumab Convert, Hepatology, Medicine +9

Cerebrovascular atherosclerosis correlates with Alzheimer pathology in neurodegenerative dementias

Mark Yarchoan, Sharon X. Xie, Mitchel A. Kling et al. · Brain · 2012 · 260 citations · Full text

Aging, Alzheimer's Disease, Vascular Risk Factors +19

Programmed Cell Death Ligand-1 (PD-L1) and CD8 Expression Profiling Identify an Immunologic Subtype of Pancreatic Ductal Adenocarcinomas with Favorable Survival

Ludmila Danilova, Won Jin Ho, Qingfeng Zhu et al. · Cancer Immunology Research · 2019 · 258 citations · Full text